Apr 19, 2026 | Allogene's Off-the-Shelf CAR-T Clears Futility Bar; Kailera Prices $625M IPO

Allogene's cema-cel drives MRD negativity in 7 of 12lymphoma patients in Phase 3 Alpha3 — stock surges 50%+. Plus: Kailera's $625M biotech IPO, UCB's $1.2B Neurona acquisition for epilepsy cell therapy, Spyre'sbest-in-class UC data, Lilly Foundayo's launch metrics, and what to watch as AACR and Q1 earnings collide this week.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Allogene, cema-cel, CAR-T, allogeneic cell therapy, lymphoma, Kailera Therapeutics, IPO, UCB,Neurona Therapeutics, epilepsy, Spyre Therapeutics, SPY001, ulcerative colitis, Entyvio, Revolution Medicines, daraxonrasib, pancreatic cancer, Eli Lilly,Foundayo, orforglipron, AACR 2026, Novo Nordisk, GLP-1, zanidatamab, Obsidian Therapeutics, TIL therapy, Lilly, Moderna